influenza virus vaccine 2025-2026 (trivalent - Georgia/Victoria/Singapore) Injectable Suspension
- RxCUI
- 2718368
- RxNorm name
- influenza virus vaccine 2025-2026 (trivalent - Georgia/Victoria/Singapore) Injectable Suspension
- Display name
- influenza virus vaccine 2025-2026 (trivalent - Georgia/Victoria/Singapore) Injectable Suspension
- Full name
- influenza virus vaccine 2025-2026 (trivalent - Georgia/Victoria/Singapore) Injectable Suspension
- Term type
- PSN
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:38:53
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 125408 | Flucelvax, Flucelvax Quadrivalent | Influenza Vaccine | 351(a) | Disc | 2026-08-01 |
UNII Substances#
No records found.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 3513dfb0-4d62-4ad1-bb15-75c7555896ff | influenza virus vaccine 2025-2026 (trivalent - Georgia/Victoria/Singapore) Injectable Suspension [PSN] · influenza A virus A/Georgia/12/2022 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Victoria/800/2024 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Singapore/WUH4618/2021 antigen 0.03 MG/ML Injectable Suspension [SCD] · influenza virus vaccine 2025-2026 (trivalent - Georgia/Victoria/Singapore) Injectable Suspension [SY] | 3 | 12 | These highlights do not include all the information needed to use FLUCELVAX ® safely and effectively. See full prescribing information for FLUCELVAX. FLUCELVAX (Influenza Vaccine) Injectable Suspension, for Intramuscular Use 2025-2026 Formula Initial U.S. Approval: 2012 | 20260305 |